ArticleJournal of cancer research and clinical oncology2026
Exploring the potential role of miR-124 in angiogenesis in colorectal cancer.
Article in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is a significant contributor to cancer-associated mortality globally, emphasizing the urgent requirement for effective therapeutic strategies. Angiogenesis, a key process in CRC progression, has garnered attention as a target for anti-cancer therapies. microRNAs (miRNAs) have emerged as potential regulators of angiogenesis in cancer, including CRC. The goal of this investigation was to discover miRNAs that regulate angiogenesis in CRC and assess the impact of selected miRNA on CRC cells.
methodsThrough an in-silico analysis of angiogenesis-related genes (ARGs), we identified miRNAs with concurrent targeting of key genes involved in CRC angiogenesis, employing bioinformatic databases. Subsequently, the suppressive impacts of overexpressed miRNA on the expression of target genes were confirmed using quantitative real-time PCR. To evaluate angiogenesis, chicken chorioallantoic membrane (CAM) assays were employed.
resultsOur computational study identified hsa-miR-124-3p, hsa-miR-16-5p, hsa-miR-1-3p, hsa-miR-101-3p, and hsa-miR-146a-5p as possible angiogenesis modulators in CRC. Among these, hsa-miR-124-3p targeted the greatest number of genes. In CRC cells, miR-124 overexpression reduced mRNA levels of ANGPT2, HIF1A, MMP9, and VEGFA genes. Furthermore, it was discovered that upregulation of miR-124 can inhibit vascularization of the CAM.
conclusionThese observations imply that miR-124 offers prospects as a potential therapy for CRC treatment. Further investigations are warranted to ascertain the therapeutic potential of miR-124-3p in animal models and patient samples. Our investigation underscores the significance of miRNAs as therapeutic targets for cancer angiogenesis and preliminary highlights the potential of miR‑124‑3p-mediated pathways as candidates for targeted intervention in CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.